Related Experiment Video
Updated: Jan 26, 2026

Quail Chorioallantoic Membrane - A Tool for Photodynamic Diagnosis and Therapy
Published on: April 28, 2022
Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy
Theodossis A Theodossiou1, Muhammad Ali2, Mantas Grigalavicius1
11Department of Radiation Biology, Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway.
Abstract:
Currently the greatest challenge in oncology is the lack of homogeneity of the lesions where different cell components respond differently to treatment. There is growing consensus that monotherapies are insufficient to eradicate the disease and there is an unmet need for more potent combinatorial treatments. We have previously shown that hypericin photodynamic therapy (HYP-PDT) triggers electron transport chain (ETC) inhibition in cell mitochondria. We have also shown that tamoxifen (TAM) enhances cytotoxicity in cells with high respiration, when combined with ETC inhibitors. Herein we introduce a synergistic treatment based on TAM chemotherapy and HYP-PDT. We tested this novel combinatorial treatment (HYPERTAM) in two metabolically different breast cancer cell lines, the triple-negative MDA-MB-231 and the estrogen-receptor-positive MCF7, the former being quite sensitive to HYP-PDT while the latter very responsive to TAM treatment. In addition, we investigated the mode of death, effect of lipid peroxidation, and the effect on cell metabolism. The results were quite astounding. HYPERTAM exhibited over 90% cytotoxicity in both cell lines. This cytotoxicity was in the form of both necrosis and autophagy, while high levels of lipid peroxidation were observed in both cell lines. We, consequently, translated our research to an in vivo pilot study encompassing the MDA-MB-231 and MCF7 tumor models in NOD SCID-γ immunocompromised mice. Both treatment cohorts responded very positively to HYPERTRAM, which significantly prolonged mice survival. HYPERTAM is a potent, synergistic modality, which may lay the foundations for a novel, composite anticancer treatment, effective in diverse tumor types.
Insights
A new combination therapy, HYPERTAM, merges hypericin photodynamic therapy (HYP-PDT) with tamoxifen (TAM) chemotherapy. This potent approach shows over 90% cancer cell death and significantly improves survival in preclinical models.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Cancer treatment faces challenges due to tumor heterogeneity and the limitations of monotherapies.
- Combinatorial treatments are needed to overcome resistance and improve efficacy.
- Previous research indicated hypericin photodynamic therapy (HYP-PDT) inhibits the mitochondrial electron transport chain (ETC), and tamoxifen (TAM) enhances cytotoxicity with ETC inhibitors.
Purpose of the Study:
- To introduce and evaluate a novel synergistic combinatorial treatment (HYPERTAM) combining TAM chemotherapy and HYP-PDT.
- To assess HYPERTAM's efficacy in two distinct breast cancer cell lines (MDA-MB-231 and MCF7) with differing metabolic profiles.
- To investigate the mechanisms of cell death, lipid peroxidation, and metabolic effects of HYPERTAM.
Main Methods:
- Testing the HYPERTAM treatment in vitro on MDA-MB-231 (triple-negative) and MCF7 (estrogen-receptor-positive) breast cancer cell lines.
- Analyzing cell death pathways (necrosis, autophagy) and measuring lipid peroxidation levels.
- Conducting an in vivo pilot study using MDA-MB-231 and MCF7 tumor models in NOD SCID-γ immunocompromised mice.
Main Results:
- HYPERTAM demonstrated over 90% cytotoxicity in both tested breast cancer cell lines.
- The treatment induced both necrosis and autophagy, accompanied by high levels of lipid peroxidation.
- In vivo studies showed significant prolongation of survival in mice bearing either MDA-MB-231 or MCF7 tumors.
Conclusions:
- HYPERTAM is a potent and synergistic therapeutic modality for cancer treatment.
- This novel combination therapy shows efficacy across diverse tumor types and metabolic profiles.
- HYPERTAM holds promise as a foundation for future composite anticancer treatments.
Related Concept Videos
Hybrid Zones
Hybridization of Atomic Orbitals I
Hybridization of Atomic Orbitals II
Resistivity
Resistance
Gene Therapy

